A passion for innovation and collaboration.

In 2003, Doug and two other investors founded Sirna Therapeutics, a first-generation RNA interference (RNAi) pioneer; he served on Sirna’s Board of Directors until the company was acquired by Merck for $1.1 billion in 2006. Other investments include Solexa, developer of the dominant ultra-high-throughput DNA sequencing platform, acquired by Illumina for $600 million; and Cambrios Technologies, which invented and now markets biologically inspired electronic materials for touch screens and flat panel displays. Before joining Oxford, Doug was a genomic scientist at the Whitehead/MIT Center for Genome Research (now known as the Broad Institute).

Doug graduated from Cornell University and obtained his Ph.D. in genetics at the University of California, Berkeley.

While at Genta, Bob became one of the only R&D executives in the biotechnology industry to follow a systemically administered oligonucleotide therapeutic (Genasense™) from the research bench through Phase 1, 2 and 3 clinical trials and NDA review. He worked directly with clinicians and study investigators on trial design, execution and interpretation of results. In addition to his roles at Genta, Bob was co-founder and vice president of research and development at Oasis Biosciences.

Bob holds a Ph.D. in molecular biology from the University of California, Berkeley, and B.S. degrees in chemistry and biology from the University of Washington.

Jack is a Certified Public Accountant (CPA) with over 30 years of financial management experience, including 20 within the biotechnology industry. He received a Master’s degree in business administration from Boston University Graduate School of Management and a Bachelor’s degree from the College of the Holy Cross majoring in Economics and Accounting.

From 1996 to 2007, she was employed at Sirna Therapeutics, Inc. (formerly Ribozyme Pharmaceuticals, Inc.).  As Director of Project Management at Sirna, she managed and was involved with all aspects of siRNA and ribozyme development programs.  Dr. Lockridge received her Ph.D. in pharmacology at the Oregon Health Sciences University, Portland, Oregon and pursued postdoctoral training at the FDA’s National Center for Toxicological Research, Jefferson, Arkansas.

At Dicerna, he has also occupied the roles of Vice President of Research Operations and of Business Development.  Dr. Miller was Senior Director, Business Development at Synta Pharmaceuticals, where he had partnering responsibility for their oncology portfolio and played a lead role in a pharma partnership, valued at over $1 billion.  Prior to this, he was Director, Business Development at Altus Biologics where his responsibilities included developing their drug delivery business and the partnering of several biological products.  Dr. Miller was a founder and the head of research for EcoScience Corporation, an agricultural biotechnology company. He began his career at Genetics Institute. Dr. Miller is the inventor on six issued United States patent.  He is a board member of EcoPesticides International, a New Mexico company, and on several public boards in his hometown of Winchester, MA.

Dr. Miller holds a Ph.D. in molecular biology and biochemistry from Harvard University and a B.S. in biochemistry and biophysics from the University of California, Davis.

Prior to joining Dicerna, Dr. Rosskamp was chief medical officer at Summit Therapeutics. In this role, Dr. Rosskamp was responsible for directing and overseeing all clinical development and medical activities for Summit’s clinical candidates in development for the rare genetic disease Duchenne muscular dystrophy and the infectious disease caused by Clostridium difficile bacteria. Prior to Summit, Dr. Rosskamp held executive-level positions in clinical research and drug development at NPS Pharmaceuticals (acquired by Shire), Ikaria, Kos Pharmaceuticals (acquired by Abbott Laboratories), Aventis Pharmaceuticals (formerly Hoechst Marrion Roussel), and Hoechst AG.

Dr. Rosskamp has been responsible for numerous investigational new drug applications, the design and execution of clinical development programs, and new drug applications across multiple therapeutic areas including diabetes, cardiovascular, respiratory and orphan drugs. Approved products for which Dr. Rosskamp was involved include Amaryl®, Lantus®, Apidra®, Simcor® and Natpara® for the treatment of a rare endocrine disease called hypoparathyroidism.

Dr. Rosskamp is a member of the Board of Directors of Bioblast Pharma in Tel Aviv, Israel. He has authored more than 20 peer-reviewed publications and published more than 50 scientific abstracts. Dr. Rosskamp is a pediatric endocrinologist with more than 15 years of experience in clinical medicine. He received his M.D. from the University of Bonn, Germany.

Prior to Dicerna, James was vice president of business development at MannKind Corporation, responsible for leading the company’s activities related to licensing, new products and strategic planning. Prior to MannKind, James held leadership positions in both business development and marketing at Pfizer Pharmaceuticals, Inc. in Tokyo, most recently as senior director of marketing. In that position, he was responsible for the sales, profit and strategic targets for the company’s specialty products, including central nervous system (CNS), endocrinology, ophthalmology and oncology therapeutics and diversified portfolios.

James holds a Bachelor of Science degree from Bates College.